| COVID-19: characteristics and therapeutics R Chilamakuri, S Agarwal Cells 10 (2), 206, 2021 | 372 | 2021 |
| Dual Targeting of PI3K and HDAC by CUDC-907 inhibits pediatric neuroblastoma growth R Chilamakuri, S Agarwal Cancers 14 (4), 1067, 2022 | 23 | 2022 |
| BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy R Chilamakuri, DC Rouse, Y Yu, AS Kabir, A Muth, J Yang, JM Lipton, ... Translational Oncology 15 (1), 101272, 2022 | 17 | 2022 |
| Exploring amodiaquine’s repurposing potential in breast cancer treatment—Assessment of In-Vitro Efficacy & Mechanism of Action V Parvathaneni, R Chilamakuri, NS Kulkarni, NF Baig, S Agarwal, ... International Journal of Molecular Sciences 23 (19), 11455, 2022 | 6 | 2022 |
| Direct targeting of the Raf-MEK-ERK signaling cascade inhibits neuroblastoma growth R Chilamakuri, S Agarwal Current Oncology 29 (9), 6508-6522, 2022 | 6 | 2022 |
| Inhibition of Polo-like Kinase 1 by HMN-214 blocks cell cycle progression and inhibits neuroblastoma growth R Chilamakuri, DC Rouse, S Agarwal Pharmaceuticals 15 (5), 523, 2022 | 6 | 2022 |
| Repurposing clofazimine for malignant pleural mesothelioma treatment—In-vitro assessment of efficacy and mechanism of action V Parvathaneni, R Chilamakuri, NS Kulkarni, X Wang, S Agarwal, V Gupta Life Sciences 306, 120843, 2022 | 3 | 2022 |
| Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth R Chilamakuri, S Agarwal Pharmaceuticals 17 (10), 1350, 2024 | | 2024 |
| Chemical Derivatization Leads to the Discovery Of Novel Analogs of Azotochelin, a Natural Siderophore, as Promising Anticancer Agents NM Karadkhelkar, P Gupta, L Barasa, R Chilamakuri, CK Hlordzi, ... ChemMedChem 19 (13), e202300715, 2024 | | 2024 |
| Direct targeting of histone deacetylases inhibits pediatric NB growth: an in vitro and in vivo study S Agarwal, R Chilamakuri The Journal of Pharmacology and Experimental Therapeutics 389, 451, 2024 | | 2024 |
| Adavosertib targets Cell Cycle Regulator WEE1 and Inhibits Pediatric Neuroblastoma Growth A Daartey, R Chilamakuri, S Agarwal The Journal of Pharmacology and Experimental Therapeutics 389, 48, 2024 | | 2024 |
| Epigenetic Targeting of DNMT1 Inhibits Neuroblastoma Growth: an in vitro and in vivo study DC Rouse, R Chilamakuri, S Agarwal The Journal of Pharmacology and Experimental Therapeutics 389, 49, 2024 | | 2024 |
| Direct targeting of the COMPASS complex inhibits neuroblastoma growth by inhibiting cancer stem cells R Chilamakuri, S Agarwal Cancer Research 84 (6_Supplement), 5120-5120, 2024 | | 2024 |
| Characterizing the Role of Epigenetic Regulator Menin in Pediatric Neuroblastoma Growth Using Pre-clinical Models R Chilamakuri | | 2024 |
| Direct Targeting of the Cell cycle Regulator WEE1 is a Novel Therapeutic Approach for Neuroblastoma P Suri, R Chilamakuri, S Agarwal The Journal of Pharmacology and Experimental Therapeutics 385, 243, 2023 | | 2023 |
| Direct Targeting of Menin-MLL1 Interaction Inhibits Cancer Stem Cells to Inhibit Neuroblastoma Growth R Chilamakuri, S Agarwal The Journal of Pharmacology and Experimental Therapeutics 385, 41, 2023 | | 2023 |
| Targeting the Cell Cycle Checkpoints CHK1 and CHK2 is a Novel Therapeutic Approach for Pediatric Neuroblastoma B Morrison, R Chilamakuri, S Agarwal The Journal of Pharmacology and Experimental Therapeutics 385, 49, 2023 | | 2023 |
| Abstract LB314: Epigenetic regulator Menin-MLL1 maintains cancer stem cells and promotes neuroblastoma growth R Chilamakuri, S Agarwal Cancer Research 83 (8_Supplement), LB314-LB314, 2023 | | 2023 |
| Inhibition of epigenetic regulator menin is a novel therapeutic approach for high-risk neuroblastoma R Chilamakuri, S Agarwal Cancer Research 82 (12_Supplement), 2957-2957, 2022 | | 2022 |
| Inhibition of PLK‐1 by using a Small Molecule Inhibitor HMN‐214 is a Novel Therapeutic Approach for High‐risk Neuroblastoma R Chilamakuri, S Agarwal The FASEB Journal 36, 2022 | | 2022 |
Saurabh AgarwalAssistant Professor, St. John's University, New Yorkยืนยันอีเมลแล้วที่ stjohns.edu